NCT02136797已完成2 期
A Phase II Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 77
- 试验地点
- 1
- 主要终点
- Complete Response
研究概览
简要总结
The purpose of this study is to see how well transfusions of T-cells work in treating CMV. Tcells are a type of white blood cell that helps protect the body from infection. A transfusion is the process by which blood from one person is transferred to the blood of another. In this case, the T-cells are made from the blood of donors who are immune to CMV. The T-cells are then grown and taught to attack the CMV virus in a lab.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Each patient must satisfy at least one of the following criteria:
- •The patient must have a clinically documented condition associated with CMV (e.g. interstitial pneumonia, hepatitis, retinitis, colitis) Or
- •The patient must have microbiological evidence of CMV viremia or tissue invasion as attested by viral culture, or detection of levels of CMV DNA in the blood or body fluids consistent with CMV infection.
- •Patient must also satisfy at least one of the following criteria:
- •The patient's CMV infection is clinically progressing or CMV viremia is persistent or increasing (as evidenced by quantitation of CMV DNA in the blood) despite two weeks induction therapy with antiviral drugs.
- •The patient has developed CMV viremia as attested by viral culture, or detection of levels of CMV DNA in blood or body fluids while receiving prophylactic doses of antiviral drugs to prevent CMV infection post transplant.
- •The patient is unable to sustain treatment with antiviral drugs due to drug associated toxicities (e.g. myelosuppression [ANC< 1000μl/ml without GCSF support] or nephrotoxicity [corrected creatinine clearance ≤ 60 ml/min/1.73 m^2 or serum creatinine > 2 mg/dl]) CMV infections are life threatening, and may involve multiple organ systems such as the lungs, liver, gastrointestinal tract, hematopoietic and central nervous systems. Antiviral drugs used for treatment may also compromise renal and hematopoietic function. Therefore, dysfunctions of these organs will not affect eligibility for this protocol.
- •Patients must meet the following clinical criteria to receive CMVpp65-CTL infusions
- •Stable blood pressure and circulation, not requiring pressor support
- •Evidence of adequate cardiac function as demonstrated by EKG and/or echocardiography.
- •A life expectancy of at least 3 weeks, even if requiring artificial ventilation.
- •There are no age restrictions
- •Patient must also satisfy at least one of the following criteria:
- •The patient's HCT donor has not been previously infected by or sensitized to CMV (e.g. a cord blood transplant or a marrow or PBSC transplant from a seronegative donor).
- •The patient's HCT donor, if seropositive, is either not available or not willing to provide leukocytes for generation of CMV-specific T-cells.
- •There are CMVpp65-specific T-cells available in appropriate doses in the MSKCC Adoptive Immune T-cell Therapy Bank that are matched with the patient for 1 HLA allele and that exhibit CMVpp65-specific cytotoxic activity that is restricted by an HLA allele shared by the patient
排除标准
- •Patients requiring high doses of glucocorticosteroids (≥ 0.3 mg/kg prednisone or its equivalent)
- •Patients who are moribund
- •Patients with other conditions not related to CMV infection (e.g. uncontrolled bacterial sepsis or invasive fungal infection) which are also life-threatening and which would preclude evaluation of the effects of a T-cell infusion.
- •Patients who are pregnant
研究组 & 干预措施
CMVpp65-CTL T-cells
Experimental
The T-cells to be infused will be selected from our bank of GMP grade CMVpp65-CTL. T-cells will be administered by bolus intravenous infusion. In this phase II trial, patients will be treated at doses of 1 x 10^6 CMVpp65-CTL/kg/dose/week for 3 weeks. Patients will be observed for the following 3 weeks. Additional 3 week courses of CMVpp65-CTL may be administered if levels of CMV DNA in blood are still detectable despite disease stabilization or improvement.
干预措施: CMVpp65 Specific T-cells (Biological)
结局指标
主要结局
Complete Response
时间窗: 2 years
defined as the clearance of the CMV infection 3-7 weeks following completion of the last cycle of CMV CTLs.
次要结局
- Number of Participants With SAE's Possibly Related to Study Treatment(2 years)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell TransplantationCytomegalovirusNCT01646645Memorial Sloan Kettering Cancer Center58
招募中
2 期
CMV-TCIP Directed Letermovir Prophylaxis After Allo-SCTCMVAllogeneic Stem Cell TransplantationNCT06453460University of California, Irvine50
终止
1 期
CMV pp65 Specific T Cell Adoptive Immunotherapy in Allogeneic Stem Cell Transplantation for Malignant DiseaseAllogeneic Stem Cell TransplantationNCT00611637H. Kim Lyerly2
进行中（未招募）
2 期
Donor Cytomegalovirus-Specific Cytotoxic T-Lymphocytes in Treating Patients With a Persistent Cytomegalovirus InfectionCytomegaloviral InfectionHematopoietic and Lymphoid Cell NeoplasmMalignant Solid NeoplasmNCT02210078M.D. Anderson Cancer Center49
暂停
1 期
Study of Adoptive Immunotherapy With Donor-derived CMV-specific T Cells for Recipients of Allo-HSCTHaematological MalignanciesCMV InfectionNCT02988258University College, London10